Journal
EXPERT OPINION ON DRUG DELIVERY
Volume 8, Issue 1, Pages 19-32Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/17425247.2011.540236
Keywords
blood-brain barrier; erythropoietin; nasal drug delivery; nervous system; neuroprotection; stroke
Categories
Ask authors/readers for more resources
Importance of the field: Erythropoietin (EPO) is a growth hormone and cytokine that plays an important role in erythropoiesis and neuroprotection. However, EPO treatment for neurological diseases requires repeated injections or high-dose systemic administration, which may cause systemic side effects. The lack of any effective treatment of acute and chronic neurodegenerative diseases and the promising outcome by EPO in animal models in vivo demand a critical evaluation of intranasal EPO delivery to the brain as an alternative administration method. Areas covered in this review: The current use and intranasal administration of EPO and its derivatives in preclinical studies and recent clinical trials with EPO in neurological diseases. What the reader will gain: This paper gives an overview of the therapeutic considerations of intranasal EPO and EPO derivatives for neuroprotection. Take home message: Intranasal delivery (ID) of neuroprotective drugs is an area of great interest. Among the administration strategies used at present, ID of EPO is the most promising. Further preclinical and clinical studies are needed to evaluate the potential significance of this alternative route for increasing EPO bioavailability and decreasing side effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available